Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of rh-prouk in STEMI Patients
NCT02367976Phase 3Unknown
- Sponsor
- Suzhou RxD Biopharmaceutical Co., Ltd.
- Start
- Jan 2015
- Primary completion
- Dec 2016
- Modality
- Metabolic Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of recombinant human prourokinase in ST-segment elevation myocardial infarction (STEMI) (2 arms), sponsored by Suzhou RxD Biopharmaceutical Co., Ltd. Primary endpoint: Percentage of patients achieving coronary recanalization at 90 minutes. Status: unknown.
02
Drugs
recombinant human prourokinase
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT02367976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02367976.